The incidence of tumor associated EGFR mutation and anaplastic lymphoma kinase (ALK) rearrangement varies from 10% (in the USA) to 35% (in East Asia) and 5–7%, respectively, in patients with NSCLC [45–48]. This evidence concerns the gene ALK and neoplasm.